Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

What is Moderna Inc.?

A biotechnology company, Moderna (MRNA), is recognized for its development of mRNA-based vaccines, notably a COVID-19 vaccine. Developments in clinical trials, regulatory approvals, and market competition continue to shape market sentiment for biotech stocks.

Why is Moderna Inc. going down?

MRNA stock is down 5.2% on Apr 2, 2026 17:01

• Moderna's decline in stock value could be linked to concerns regarding slow enrollment in COVID-19 vaccine trials, mirroring issues observed with Pfizer and BioNTech. This trend suggests potential difficulties in gathering post-marketing data and a waning interest in COVID-19 vaccines.
• The temporary pause in vaccine trial enrollment may have instilled uncertainty among investors concerning the vaccine development timeline and regulatory clearance, resulting in a negative impact on Moderna's stock performance.
• Investor attention appears to be shifting towards other biotech entities such as Allogene Therapeutics, benefiting from positive sector trends and experiencing a rise in stock prices. This redirection of focus and investment away from Moderna potentially contributed to its recent decline.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment

Pfizer and BioNTech have halted enrollment in a large U.S. trial for their updated COVID-19 vaccine due to slow recruitment of healthy adults aged 50-64, preventing the generation of relevant post-marketing data. Moderna is reportedly facing similar issues with its own vaccine trial in the same age group, which follows new FDA requirements for placebo-controlled data. The challenges highlight difficulties in clinical trial enrollment and a potential dip in interest in COVID-19 vaccines in the U.S. market.

https://www.biospace.com/drug-development/pfizer-biontech-halt-large-us-covid-19-vaccine-trial-over-slow-enrollment

NuCana plc Stock: Prodrug Technology Platform Targets Oncology Challenges for Long-Term Investor Value

NuCana plc, a clinical-stage biopharmaceutical company, utilizes its proprietary ProTide technology to enhance the delivery and efficacy of nucleoside analog cancer drugs, targeting unmet medical needs in oncology. The company's pipeline includes Nadacomotide (NUC-3373) for colorectal cancer and Acelarin (NUC-1031) for broader solid tumor applications, with earlier-stage candidates also in development. North American investors can access NuCana shares (NCNA) on NASDAQ, offering exposure to a company with a focused development strategy in the growing oncology market, though trial risks and funding remain key watchpoints.

https://www.ad-hoc-news.de/boerse/news/ueberblick/nucana-plc-stock-prodrug-technology-platform-targets-oncology-challenges/69055273

Allogene Therapeutics Stock Gains Momentum from Sector Tailwinds ()

Allogene Therapeutics is experiencing a surge in stock value due to a positive shift in the biotechnology sector, driven by strategic acquisitions and licensing deals. The cell therapy specialist's clinical pipeline is attracting institutional investors, pushing its stock close to its yearly peak with an approximately 96% gain since the start of the year. Future growth hinges on concrete data readouts from its research pipeline and further industry consolidation.

https://www.aktiencheck.de/news/Artikel-Allogene_Therapeutics_Stock_Gains_Momentum_from_Sector_Tailwinds-19625941

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?

Rhythm Pharmaceuticals (RYTM) saw a 12.6% jump in its stock price, attributed to a positive opinion from the European Medicines Agency regarding the expansion of Imcivree's marketing authorization. Despite this rally, the company faces a 2% lower consensus EPS estimate for the upcoming quarter, raising questions about sustained strength. The stock currently holds a Zacks Rank #3 (Hold).

https://qz.com/strength-seen-in-rhythm-pharmaceuticals-rytm-can-its-12-6-jump-turn-into-more-strength

Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is proposing to expand its 2019 Omnibus Incentive Plan by adding 3.5 million shares, increasing the total authorized shares to 10.5 million, and extending the plan's term by ten years. This proposal will be voted on at the annual shareholder meeting on May 20, 2026, alongside the election of directors, ratification of Baker Tilly US, LLP as auditors, and an advisory vote on executive compensation. The company states the expansion is crucial for attracting, motivating, and retaining talent and aligns with its pay-for-performance compensation philosophy.

https://www.stocktitan.net/sec-filings/DMAC/def-14a-dia-medica-therapeutics-inc-definitive-proxy-statement-e72e63605464.html

Trending Today

Moderna Inc. Price History

02.03.2026 - MRNA Stock was down 5.2%

• Moderna's decline in stock value could be linked to concerns regarding slow enrollment in COVID-19 vaccine trials, mirroring issues observed with Pfizer and BioNTech. This trend suggests potential difficulties in gathering post-marketing data and a waning interest in COVID-19 vaccines.
• The temporary pause in vaccine trial enrollment may have instilled uncertainty among investors concerning the vaccine development timeline and regulatory clearance, resulting in a negative impact on Moderna's stock performance.
• Investor attention appears to be shifting towards other biotech entities such as Allogene Therapeutics, benefiting from positive sector trends and experiencing a rise in stock prices. This redirection of focus and investment away from Moderna potentially contributed to its recent decline.

02.03.2026 - MRNA Stock was down 5.7%

• Moderna's stock experienced a bearish movement today, possibly influenced by:
• Pfizer and BioNTech halting enrollment in a large U.S. COVID-19 vaccine trial due to slow recruitment, reflecting potential challenges and decreased interest in vaccine trials.
• Market sentiment shifting towards Allogene Therapeutics, which is gaining momentum in the biotechnology sector with positive clinical pipeline developments, diverting attention from Moderna.
• Mixed trade ideas and technical analyses on Moderna's stock from traders, indicating uncertainty and varied perspectives on its future movements.
• The bearish trend in Moderna's stock today could be a result of concerns regarding vaccine trial enrollment, competition in the biotech sector, and divergent market analyses, leading to a decline in investor confidence in the short term.

18.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock declined by 3.77% today.
• Institutional selling pressure, specifically with one entity reducing its stake, has impacted the stock causing short-term uncertainty.
• Despite exceeding earnings expectations and receiving positive feedback on its mRNA flu vaccine from regulatory authorities, the stock is facing a downward trend due to conflicting technical indicators and expert opinions.
• Market sentiment towards Moderna remains cautious as worries about potential risks outweigh recent company achievements and progress in precision medicine.

18.02.2026 - MRNA Stock was down 5.7%

• Moderna Inc. (MRNA) encountered a downward trend in the market today, grappling with obstacles related to its pipeline projects and financial pressures.
• Factors such as decreased demand for its COVID-19 vaccine, Spikevax, and scrutiny surrounding its pipeline advancements have influenced the stock's downturn.
• Investors are reassessing the company's future prospects as Moderna transitions focus towards diverse therapies like mRNA oncology and rare diseases, causing uncertainties in the market.
• Despite holding a substantial cash reserve, notable R&D expenses, and varied efficacy outcomes in certain trials, Moderna's stock performance has been adversely affected by the challenges it is currently facing.

01.03.2026 - MRNA Stock was up 5.3%

• The recent upward trend in Moderna's stock price can be linked to its strategic shift towards oncology research and the development of next-gen respiratory solutions, underscoring a focus on sustained growth opportunities extending beyond the realm of pandemic-related vaccines.
• Investor enthusiasm is likely fueled by Moderna's dedicated efforts in oncology, particularly the promising outcomes in personalized neoantigen therapy for melanoma, signaling positive market responses to the company's diversification.
• Moderna's target of achieving profitability by 2028, backed by a substantial cash reserve and a recent legal settlement, instills further confidence among investors regarding the company's trajectory.
• Noteworthy progress in resolving the ongoing patent dispute with Arbutus Biopharma Corp (ABUS) may have also contributed to the positive momentum of Moderna's stock, as a favorable resolution in legal matters could help alleviate uncertainties for stakeholders.

27.02.2026 - MRNA Stock was down 6.0%

• Moderna's stock (MRNA) faced a bearish movement, potentially attributed to profit-taking following a period of strong performance.
• Despite being a key player in the biotech industry and expanding its pipeline, investors may have reacted cautiously to potential challenges in the vaccine market and broader biotech sector.
• The company's shift towards treatments for respiratory viruses, oncology, and rare diseases may not have immediately captured market optimism, contributing to the bearish movement.
• The market's trajectory could also be influenced by general sector trends or broader economic factors impacting investor sentiment towards biotech stocks.

27.02.2026 - MRNA Stock was down 5.1%

• Moderna's stock experienced a significant drop today, possibly influenced by the broader market sentiment affected by the U.S.-Iran conflict and policy deadlines.
• The internal realignment by Vanguard, resulting in 0 reported shares, might have also contributed to the downward pressure on Moderna's stock.
• Despite ongoing growth potential from strategic partnerships and promising pipelines, the stock faced short-term selling pressure, reflecting investor concerns.
• The market's negative reaction to the overall uncertainty and rising oil prices could have led to the decline in Moderna's stock, creating potential buying opportunities for investors eyeing high-quality stocks.

27.02.2026 - MRNA Stock was down 5.2%

• A realignment announcement by Vanguard of 0 MRNA shares might have created uncertainty among investors, leading to a sell-off of Moderna stock.
• The comparison between ImmunityBio and Moderna, highlighting Moderna's broader pipeline and financial stability, could have influenced investors to shift their focus towards ImmunityBio, impacting Moderna's stock price negatively.
• Despite being a leading player in the biotech sector and strategically diversifying its pipeline, Moderna's stock might have faced downward pressure due to concerns about the company's ability to sustain growth beyond its COVID-19 vaccine.
• The potential for significant growth over the next five years for Moderna might not have been enough to offset the immediate bearish sentiment surrounding the stock today.

17.02.2026 - MRNA Stock was up 5.5%

• Today's positive movement in Moderna's stock price is linked to a recent federal court decision blocking proposed changes to the U.S. vaccine policy, a move by Health Secretary Robert F. Kennedy Jr. This ruling has provided stability for Moderna amidst concerns of policy changes impacting biotech revenues.
• Noteworthy insider selling by key individuals such as Moderna President Stephen Hoge, alongside decreased stake holdings by investment entities like Militia Capital Partners LP, contrasts the company's robust financial performance. With $1.9 billion in total revenue for 2025, investor trust in Moderna remains strong.
• The introduction of IQVIA.ai, an advanced AI platform developed in partnership with NVIDIA, to enhance operational efficiency and decision-making in the life sciences domain, may have positively influenced market sentiment towards forward-thinking biotech firms like Moderna.
• Criticism directed at the FDA for inconsistent actions, particularly concerning Moderna's vaccine submissions, underscores regulatory uncertainties that could impact the company's future initiatives and market dynamics. Nonetheless, Moderna's resilience and expansion beyond COVID-related products could help mitigate potential risks.

31.02.2026 - MRNA Stock was up 5.3%

• The positive investor sentiment towards the company's strategic shift towards oncology and next-generation therapies is likely the driving force behind the recent bullish movement of the company's stock.
• Favorable data on individualized neoantigen therapy for melanoma and the company's emphasis on cancer drug development are factors contributing to the market's positive response to the company's new direction.
• The selling of shares by an insider at a different company may have indirectly impacted the company's stock positively, potentially leading investors to view the company's strategic pivot more favorably.
• The company's proactive approach to diversifying its portfolio and focusing on innovative therapies appears to have resonated well with investors, leading to the upward movement in its stock price.

11.02.2026 - MRNA Stock was up 5.6%

• Reduction of stake in Moderna by 25.3% by Jefferies Financial Group initially sparked concerns regarding the company's future outlook. However, the strong bullish movement today indicates ongoing investor optimism towards Moderna's growth potential.
• Uptick in Moderna's stock following US vaccine advisors' decision not to question mRNA COVID shots could have boosted investor confidence in the company. This move reaffirms faith in mRNA technology, crucial for Moderna's vaccine innovation.
• Moderna's stock surged 6.13% to hit a day high, outperforming the S&P 500. This indicates a positive market response to the company's recent performance and its potential for future growth, despite past long-term declines.
• Favorable sentiment in the therapeutics sector, marked by companies surpassing revenue expectations, may have also contributed to the bullish movement in Moderna's stock. Investors are demonstrating increased interest in the healthcare industry overall.

12.02.2026 - MRNA Stock was down 5.1%

• The decline in Moderna's stock could be linked to profit-taking by institutional investors such as Jefferies Financial Group, which notably decreased its holdings in the company.
• Resolving patent disputes related to its COVID-19 vaccine possibly created uncertainty among investors, despite the settlement and licensing agreements in place.
• Reports of a federal vaccine advisory panel scrapping plans to scrutinize mRNA COVID shots might have raised worries about regulatory challenges or public reception of Moderna's mRNA technology.
• Analysts' consensus "Reduce" rating and apprehensions about inflated valuations likely added to the negative sentiment surrounding Moderna's stock movement.